Author: Thomas Yorio

Publisher: Academic Press

Published: 2011-04-28

Total Pages: 537

ISBN-13: 0080556779

Ocular Therapeutics: Eye on New Discovery focuses on emerging areas in ocular research, from new approaches to dry eye to gene therapy in the management of retinal diseases. This comprehensive book features more than 25 chapters of information that will be vital for ocular investigators and ophthalmologists bringing them new information on promising therapeutics. It is the intent of this book to provide not only information on current approaches to treatment, but also in giving the reader a greater understanding as to what may become available for treating a number of important eye diseases. Each chapter features some new aspect of treatment that holds great promise for the future. The approach has been to concentrate on those areas of ocular diseases that are more prevalent. It also features new insight for drug delivery and for managing devasting diseases, such as macula edema and glaucoma, two of the leading causes of blindness in the United States. This book will serve as an important resource as it contains a number of relevant references highlighted for their importance to the field. New investigators will be able to obtain an historical perspective for each of the topics and to develop an understanding of the new research directions that are underway. Ocular Therapeutics: Eye on New Discovery is more than a reference book, as it also provides an important glimpse into the near future.* Contains information that is vital for ocular investigators and ophthalmologists bringing them new information on promising therapeutics.* Provides not only information on current approaches to treatment, but also gives the reader a greater understanding as to what may become available for treating a number of important eye diseases.* Historical perspective for each of the topics as well as an important glimpse into the near future to develop an understanding of the new research directions underway.* New insight for drug delivery and for managing devastating diseases, such as macula edema and glaucoma, two of the leading causes of blindness in the United States